Camilia has a remarkable safety record since it first debuted on the market in 1994. This medicine is relied upon by parents in nearly 20 countries, including Canada and France where it is a top-seller with high consumer satisfaction.
As with all of Boiron’s over-the-counter medicines, Camilia’s marketing and production are regulated as a drug. It is manufactured according to the high standards of drug Good Manufacturing Practices (GMP), and conforms to the requirements of the Homeopathic Pharmacopoeia of the United States.
Boiron has a strong history of regulatory compliance and has never received a warning letter from FDA for any product, including Camilia, since opening its U.S. office in 1983.
The Boiron family has prided itself on delivering high-quality and reliable products since 1932. Today the global headquarters adheres to regulations for the more than 50 countries in which it distributes its drug products.